Science Corp launches Prima in Europe — the first BCI cleared to restore reading vision

Science Corporation announced the European commercial launch of PRIMA, its vision-restoring retinal implant, after receiving a CE mark authorizing sale across 30 European countries. PRIMA is a subretinal photovoltaic chip paired with camera glasses that project near-infrared light onto the implant, which converts it into electrical stimulation — restoring functional central vision to patients blinded by geographic atrophy, the advanced form of dry age-related macular degeneration. In the trial behind the approval (reported in the New England Journal of Medicine), 80% of patients showed meaningful visual-acuity gains and could read letters, numbers and words. It's the first BCI cleared anywhere for form-vision restoration. Science plans to begin in Germany, where the first commercial procedure could take place as early as September.

Why it matters

This is the second commercial BCI approval to land in months, and it widens the definition of the category. Where Neuracle's NEO restores motor function via a market approval in China, PRIMA restores a sense — vision — under an EU CE mark, for a condition (AMD) that affects millions rather than a rarer injury population. The pattern that the first-human implants only hinted at is now explicit: BCIs are reaching patients through conventional medical-device regulatory paths, not just investigational trials, and doing it first outside the US. For a field whose milestones have mostly been "first human implant," "first commercial launch for a mass-prevalence disease" is a different order of validation.

What to watch

Uptake and reimbursement in Germany and the next EU markets, real-world visual outcomes beyond the trial cohort, and whether Science pursues a US FDA pathway now that a European commercial base exists.